InMed Pharmaceuticals (INM) EBITDA (2019 - 2026)

InMed Pharmaceuticals has reported EBITDA for 8 years, with the latest figure at -$2.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 47.26% year-over-year to -$2.8 million; the trailing twelve-month figure through Mar 2026 stood at -$9.2 million (down 16.27% YoY), and the FY2025 full-year result was -$7.9 million, up 3.1% from the prior year.
• EBITDA for Q1 2026 stood at -$2.8 million, down from -$2.1 million in the prior quarter.
• The five-year high for EBITDA was -$472234.0 in Q2 2023, with the low at -$7.9 million in Q2 2022.
• Historically, EBITDA has averaged -$2.5 million across 5 years, with a median of -$2.1 million in 2022.
• Annual changes were most pronounced in 2023 — EBITDA jumped 94.0% — and 2024, when it plunged 329.61%.
• InMed Pharmaceuticals' EBITDA stood at -$2.1 million in 2022, then increased by 22.39% to -$1.6 million in 2023, then plunged by 37.47% to -$2.2 million in 2024, then increased by 6.21% to -$2.1 million in 2025, then slumped by 32.78% to -$2.8 million in 2026.
• The last three EBITDA figures came in at -$2.8 million (Q1 2026), -$2.1 million (Q4 2025), and -$1.8 million (Q3 2025), per Business Quant data.